Related references
Note: Only part of the references are listed.Intrathecal administration of nusinersen in adolescent and adult SMA type 2 and 3 patients
Claudia D. Wurster et al.
JOURNAL OF NEUROLOGY (2019)
Neurofilaments and tau in CSF in an infant with SMA type 1 treated with nusinersen
Benedikt Winter et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2019)
Intrathecal nusinersen treatment for SMA in a dedicated neuromuscular clinic: an example of multidisciplinary and integrated care
Valeria A. Sansone et al.
NEUROLOGICAL SCIENCES (2019)
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
E. Mercuri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Feasibility and safety of intrathecal treatment with nusinersen in adult patients with spinal muscular atrophy
Benjamin Stolte et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2018)
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
R. S. Finkel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Intrathecal Injections in Children With Spinal Muscular Atrophy: Nusinersen Clinical Trial Experience
Manon Hache et al.
JOURNAL OF CHILD NEUROLOGY (2016)
Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study
Richard S. Finkel et al.
LANCET (2016)
Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy
Claudia A. Chiriboga et al.
NEUROLOGY (2016)
Importance of Follow-Up Cerebrospinal Fluid Analysis in Cryptococcal Meningoencephalitis
Thomas Skripuletz et al.
DISEASE MARKERS (2014)
Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model
Yimin Hua et al.
GENES & DEVELOPMENT (2010)
Share Paper
